Nymox Pharmaceutical (Nymox Pharmaceutical) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical ROE % Adjusted to Book Value?

Nymox Pharmaceutical's ROE % for the quarter that ended in Sep. 2023 was 0.00%. Nymox Pharmaceutical's PB Ratio for the quarter that ended in Sep. 2023 was N/A. Nymox Pharmaceutical's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was N/A.

Nymox Pharmaceutical ROE % Adjusted to Book Value Historical Data

The historical data trend for Nymox Pharmaceutical's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical ROE % Adjusted to Book Value Chart

Nymox Pharmaceutical Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-30.37

-5.50

-4.74

Nymox Pharmaceutical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-7.66	-	-	-	-

Competitive Comparison of Nymox Pharmaceutical's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Nymox Pharmaceutical's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's ROE % Adjusted to Book Value falls into.

Nymox Pharmaceutical ROE % Adjusted to Book Value Calculation

Nymox Pharmaceutical's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Nymox Pharmaceutical's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Nymox Pharmaceutical ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel